ENA0000GenomicsMultiomicsFundació Clínic per a la Recerca Biomèdicahttps://www.ebi.ac.uk/ena/browser/view/PRJNA148679Homo sapiensDocetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer. However, most patients eventually develop resistance to this treatment. The aim of the study was to identify key molecular genes and networks associated with docetaxel resistance in 2 models of docetaxel-resistant castration-resistant prostate cancer cell lines. Overall design: DU-145 and PC-3 cells were converted to docetaxel-resistant cells, DU-145R and PC-3R, respectively. Whole-genome arrays were used to compare global gene expression between these 4 cell lines. Arrays were performed by triplicate for each cell line.ENAdata, RP 56976, insensitive, prostate cancer cell, (2aR, Docetaxel Anhydrous, 4S, 10, Taxotere, 11, 12, 13, 13-tetramethyl-5-oxo-7, N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol, RP-56976, beta-(((1, (alphaR)-, 4a, 11S, 3, 4, 11-tetrahydroxy-8, 5, 6, hydrate (1:3), 9, 9S, Taxoltere Metro, Benzenepropanoic acid, 12b-dodecahydro-4, 4aR, resistant, 1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12S, 2-b)oxet-9-yl ester, 12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a, 4)benz(1, Docetaxol, 6R, Docetaxel Trihydrate, prostate tumour cell., RP56976, 12a, 11-methano-1H-cyclodeca(3, prostate tumor cell, 12aS, N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol, Docetaxel Hydrate, NSC 628503, prostate carcinoma cellhuman being, human., man0.00.00.00.00.00falseHomo sapiensExpression data from docetaxel-resistant prostate cancer cell lines2022-05-122014-02-11PRJNA148679GSE33455220276949606